QPPV.COM KNOWLEDGE ASSESSMENT

GVP Module IX: Signal Outcomes and Regulatory Action — Knowledge Assessment

Test your understanding of the concepts covered by GVP Module IX: Signal Outcomes and Regulatory Action.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why must an organisation identify whether a product is centrally or nationally authorised before planning implementation of an EU signal recommendation?

Authorisation status determines whether the event is medically serious The applicable regulatory route and implementation pathway can differ by authorisation status Nationally authorised products are outside pharmacovigilance requirements Centrally authorised products do not require product-information control

Question 2 of 10 Which record would provide the strongest justification for closing a signal with no new regulatory action?

A status field stating 'closed' without supporting information A record documenting the evidence, conclusion, remaining uncertainty, existing controls and rationale for no additional action A list of all people copied on the closure email A regulatory outcome copied from another product

Question 3 of 10 Why should a signal outcome be connected to the risk management plan even if product information does not immediately change?

Because every signal automatically requires an RMP revision Because the safety specification, pharmacovigilance activities or risk-minimisation measures may still need reassessment Because the RMP replaces the scientific signal assessment Because product information can only be changed after an RMP is deleted

Question 4 of 10 Which sequence best preserves the conceptual distinction between the main stages of signal management?

Regulatory action, signal detection, scientific assessment, monitoring Signal detection, scientific assessment, safety conclusion, pharmacovigilance decision, regulatory assessment where applicable Scientific assessment, regulatory action, signal validation, risk-management decision Signal detection, product-information change, causality confirmation, regulatory assessment

Question 5 of 10 Which statement best describes a legitimate no-further-action decision?

It means the signal was never scientifically assessed It is acceptable only when the association has been disproven beyond any doubt It may be appropriate when evidence and existing controls show that additional action is not currently justified It automatically means that routine pharmacovigilance can stop

Question 6 of 10 Which statement best reflects the role of regulatory action when scientific uncertainty remains?

Regulatory action is impossible until complete certainty is achieved Uncertainty may justify proportionate action, particularly for serious potential risks, provided the uncertainty is accurately described Any regulatory action establishes confirmed causality Uncertainty should be omitted from communications once action is taken

Question 7 of 10 Which item is most important when designing additional evidence generation for a signal?

Selecting the largest possible dataset regardless of the uncertainty Ensuring that the study or analysis is capable of addressing the specific unresolved question Using the same design for every type of safety concern Deferring definition of the study objective until after results are available

Question 8 of 10 Which factor is least consistent with a proportionate benefit-risk assessment of a signal?

Seriousness and frequency of the event Magnitude and certainty of the risk Effectiveness of existing risk-minimisation measures The number of internal departments involved in the assessment

Question 9 of 10 What does closure of a signal most accurately mean?

The event can never occur with the medicine The available evidence does not currently justify maintaining the issue as an active signal All future cases involving the event should be excluded from surveillance The original report was necessarily invalid

Question 10 of 10 A signal assessment finds that the association is plausible but the available evidence is insufficient for a definitive intervention. Which outcome is generally most appropriate?

Immediate withdrawal of the medicine in all markets Automatic closure without further review Targeted evidence generation linked to the unresolved uncertainty Automatic revision of all product information

GVP Module IX: Signal Outcomes and Regulatory Action — Knowledge Assessment

Cookie Settings